RxDoctor Payments Data

Walter Goula, MD

Internal Medicine · Providence, RINPI 1144285859

Payments from drug & device makers

$2,032in general payments, 2019–2025

Across 108 payments — averaging $18.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$354
  • AstraZeneca$325
  • Pfizer$280
  • AbbVie$204
  • Teva Pharmaceuticals USA, Inc.$143
  • Viiv Healthcare Company$84
  • plus $642 from 17 others

What the payments were for

  • Food & beverage$2,032100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,032 in reported general payments places this provider in the 85th percentile of 808 internal medicine providers in Rhode Island.

See all internal medicine providers in Rhode Island

Medicare billing

Part B allowed, 2024
$51,250
Medicare patients
171
Services billed
1,658

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin55$55,056
EliquisApixaban46$48,093
OzempicSemaglutide40$43,594
XareltoRivaroxaban32$35,105
RybelsusSemaglutide15$34,685
TrulicityDulaglutide17$29,822
FarxigaDapagliflozin Propanediol16$22,415
Janumet XrSitagliptin Phos/Metformin Hcl20$15,084
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$13,155
MounjaroTirzepatide11$10,865
MyrbetriqMirabegron11$9,638
Atorvastatin Calcium523$6,495
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate15$6,124
Omeprazole364$6,024
Breo ElliptaFluticasone/Vilanterol12$5,069

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$354$78,27955 claims
PfizerEliquis$280$48,09346 claims
Lilly USA, LLCTrulicity, Mounjaro$62$40,68728 claims
Johnson & JohnsonXarelto$30$35,10532 claims
AstraZenecaFarxiga$325$22,41516 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$45$21,40142 claims
MerckJanumet Xr$78$15,08420 claims
AbbVieSynthroid$204$1,57929 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 808 internal medicine providers in Rhode Island.

Other internal medicine in Providence

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →